Aquestive Licenses LIBERVANT to Eton for $10M Upfront, Up to $47.5M in Milestones
AQST sits 63% above its 52-week low of $2.93.
Summary
Aquestive granted Eton Pharmaceuticals exclusive U.S. rights to LIBERVANT for $10 million upfront, up to $47.5 million in milestones, and mid-teens royalties, with commercial launch targeted for April 2027.
Updates
· Seeking Alpha — Eton expects to launch Libervant next year, subject to final FDA approval.
- Milestone payments are worth up to $45 million.
- FDA granted tentative approval for ages 2 to 5 years and 12 years and above.
Key Events · M&A and Partnerships · AQST
-
Exclusive U.S. License for LIBERVANT
Aquestive granted Eton Pharmaceuticals exclusive U.S. commercialization rights to LIBERVANT (diazepam) buccal film for seizure clusters, receiving a $10.0 million upfront fee.
-
Milestone and Royalty Economics
Aquestive is eligible for up to $47.5 million in regulatory and commercial milestones — including $10 million on first commercial sale (reduced to $5 million without full ages 2-5 approval) and up to $35 million tied to annual net sales — plus mid-teens percentage royalties.
-
20-Year Supply Agreement
Aquestive will serve as exclusive manufacturer and supplier to Eton under a 20-year initial term with automatic three-year renewals, adding a long-term CDMO revenue stream.
-
Regulatory Timeline
Full approval for ages 12+ is expected after VALTOCO's orphan exclusivity expires January 10, 2027; a separate PDUFA date of March 29, 2027 covers ages 6-11 label expansion; commercial launch targeted for April 2027.
Analysis · AQST · Life Sciences
Aquestive monetizes its tentatively approved LIBERVANT buccal film by handing U.S. commercialization to Eton Pharmaceuticals, receiving $10 million upfront plus up to $47.5 million in milestones and mid-teens royalties. The deal converts a stranded asset into near-term cash and a future royalty stream while Eton funds the commercial build-out. For a company that reported a $22.9 million quarterly net loss and $98.5 million in cash as of late September, the upfront payment is meaningful non-dilutive capital. The April 2027 launch target hinges on FDA full approval after VALTOCO's orphan exclusivity expires January 10, 2027, and a separate PDUFA decision on March 29, 2027 for ages 6-11.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AQST was trading at $4.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $586.1M. The 52-week trading range was $2.93 to $7.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.